Woolsey Pharmaceuticals Unveils Promising Results in ALS Treatment with BRAVYL® Reducing Toxic TDP-43 Spread Woolsey Pharmaceuticals announces groundbreaking findings showing the potential of BRAVYL in significantly reducing the spread of TDP-43 pathology in ALS patients, offering new hope for treatment.

Woolsey Pharmaceuticals Unveils Promising Results in ALS Treatment with BRAVYL® Reducing Toxic TDP-43 Spread #United_States #New_York #ALS_Research #Woolsey_Pharma #BRAVYL